{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:44:46Z","timestamp":1774863886165,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: The long-term effects of rheumatoid arthritis (RA) therapies on bone mineral density (BMD) remain incompletely characterized. We aimed to evaluate BMD trajectories over an 8-year follow-up in patients with RA treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biological DMARDs (bDMARDs) in real-world practice. Methods: Patients were selected from an observational RA cohort established at Nice University Hospital between 2001 and 2016. Participants were classified into two groups according to treatment regimen (csDMARD only or any bDMARD exposure). BMD was assessed by dual-energy X-ray absorptiometry at baseline and after 1, 2, 3, 5, and 8 years at the lumbar spine, femoral neck, and total hip. Longitudinal changes in BMD were analyzed using multivariable linear mixed-effects models adjusted for age, sex, body mass index (BMI), disease duration, seropositivity, glucocorticoid use, anti-osteoporosis treatment, and clinical response. Results: A total of 312 patients were included, of whom 181 received bDMARDs and 131 were treated exclusively with csDMARDs. BMD showed limited change during the first two years in both groups. Beyond two years, modest declines were observed at hip sites at subsequent time points, whereas lumbar spine BMD did not demonstrate significant longitudinal change in pointwise analyses. In mixed-effects models, the treatment group\u2013time interaction was significant for lumbar spine (p = 0.004) and total hip (p = 0.04), but not for the femoral neck (p = 0.34), indicating differential BMD trajectories over time between treatment groups. In the csDMARD group, lumbar spine and total hip BMD decreased by a mean of 0.0006 and 0.0005 g\/cm2 per month, respectively, whereas no significant slopes were observed in the bDMARD group. Older age was associated with lower BMD, while male sex and higher BMI were associated with higher BMD across sites. Conclusions: In this long-term real-world cohort, BMD remained relatively stable during the first two years of follow-up. Longitudinal analyses suggested a less pronounced decline in lumbar spine and total hip BMD trajectories among bDMARD-treated patients compared with those receiving csDMARD alone, underscoring the need for ongoing bone health monitoring in RA.<\/jats:p>","DOI":"10.3390\/jcm15072594","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:22:36Z","timestamp":1774858956000},"page":"2594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Effects of Rheumatoid Arthritis Treatments on Bone Mineral Density: 8-Year-Follow-Up Data from Real-World Practice"],"prefix":"10.3390","volume":"15","author":[{"given":"Louis-Edmond","family":"Barbaro","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Bustamente","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5847-5450","authenticated-orcid":false,"given":"L\u00e9a","family":"Evenor","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9204-0397","authenticated-orcid":false,"given":"Angelina","family":"Villain","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdellahi","family":"Vall","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-1322","authenticated-orcid":false,"given":"Roxane","family":"Fabre","sequence":"additional","affiliation":[{"name":"Department of Public Health, University C\u00f4te d\u2019Azur, 06000 Nice, France"},{"name":"Cognition Behavior Technology Laboratory, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6565-8212","authenticated-orcid":false,"given":"Laurent","family":"Bailly","sequence":"additional","affiliation":[{"name":"Department of Public Health, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Breuil","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pradier","sequence":"additional","affiliation":[{"name":"Department of Public Health, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-9346","authenticated-orcid":false,"given":"Christian","family":"Roux","sequence":"additional","affiliation":[{"name":"LAMHESS Laboratory, Rheumatology Department, University C\u00f4te d\u2019Azur, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00198-010-1319-x","article-title":"Osteoporosis in inflammatory joint diseases","volume":"22","author":"Roux","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","article-title":"Generalised bone loss in patients with early rheumatoid arthritis","volume":"344","author":"Gough","year":"1994","journal-title":"Lancet"},{"key":"ref_4","first-page":"683","article-title":"Factors influencing bone loss in rheumatoid arthritis: A longitudinal study","volume":"18","author":"Cortet","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_5","first-page":"2541","article-title":"The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis?","volume":"27","author":"Sambrook","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegeriny osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.2003.008458","article-title":"Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor \u03b1, interleukin 1, and receptor activator of nuclear factor \u03baB ligand (RANKL) regulate osteoclasts","volume":"63","author":"Ireland","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cyto.2015.08.260","article-title":"The role of cytokines in the pathogenesis of rheumatoid arthritis\u2014Practical and potential application of cytokines as biomarkers and targets of personalized therapy","volume":"76","author":"Brzustewicz","year":"2015","journal-title":"Cytokine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"I96","DOI":"10.1136\/ard.58.2008.i96","article-title":"Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist","volume":"58","author":"Bresnihan","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE","volume":"71","author":"Tak","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1297-319X(12)70011-8","article-title":"Abatacept therapy and safety management","volume":"79","author":"Pham","year":"2012","journal-title":"Jt. Bone Spine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti\u2013tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000165777","article-title":"Efficacy of Biologicals in the Treatment of Rheumatoid Arthritis","volume":"83","author":"Venkateshan","year":"2009","journal-title":"Pharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Haugeberg, G., Helgetveit, K.B., F\u00f8rre, \u00d8., Garen, T., Sommerseth, H., and Pr\u00f8ven, A. (2014). Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-289"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","article-title":"Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: A cohort study","volume":"52","author":"Krieckaert","year":"2013","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.2008.091611","article-title":"Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: Arrest of bone loss","volume":"68","author":"Wijbrandts","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF\u03baB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Delpech, C., Laborne, F.-X., and Hilliquin, P. (2022). Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010286"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.phrs.2024.107074","article-title":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project","volume":"200","author":"Ingrasciotta","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4078\/jrd.22.0046","article-title":"Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis","volume":"30","author":"Kim","year":"2023","journal-title":"J. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-020-02231-x","article-title":"Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register","volume":"22","author":"Vela","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2147\/BTT.S2338","article-title":"Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNF\u03b1 therapy","volume":"2","author":"Miossec","year":"2008","journal-title":"Biol. Targets Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-010-1462-4","article-title":"Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis","volume":"22","author":"Confavreux","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/acr.22519","article-title":"Meta-Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials","volume":"67","author":"Siu","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1196\/annals.1351.040","article-title":"Bone Metabolism Changes During Anti-TNF-\u03b1 Therapy in Patients with Active Rheumatoid Arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2007.073817","article-title":"Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis","volume":"67","author":"Bijsterbosch","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","first-page":"3416","article-title":"Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"25","author":"Shao","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/S1516-31802002000100003","article-title":"Impact of degenerative radiographic abnormalities and vertebral fractures on spinal bone density of women with osteoporosis","volume":"120","author":"Paiva","year":"2002","journal-title":"Sao Paulo Med. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.bonr.2018.100190","article-title":"Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification","volume":"10","author":"Bristow","year":"2019","journal-title":"Bone Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:44:42Z","timestamp":1774860282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072594"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072594","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}